AffaMed Therapeutics
Führungskräfte
Siehe das Organigramm mit seine 8 wichtigsten Führungskräfte
Die meist gesuchten Biographien bei AffaMed Therapeutics
- Vijay Karwal, Chief Executive Officer and Chief Financial Officer
- Michael Keyoung, Director
- Lucia Qian, Director
Eine Benachrichtigung erstellen
um Veränderungen bei Führungskräften von AffaMed Therapeutics nachzuverfolgen.
Biotechnologie
AffaMed Therapeutics hat 2.292 Konkurrenten , einschließlich Eurofins (Luxemburg), Lonza (Schweiz) und Adaptive Phage Therapeutics (USA).
Popular M&A news in Biotechnologie
- Lycia Therapeutics hat gerade eine Spendenaktion von 107 Millionen Dollar angekündigt. (veröffentlicht am 15, Mai 2024).
- Attovia Therapeutics hat gerade eine Spendenaktion von 150 Millionen Dollar angekündigt. (veröffentlicht am 14, Mai 2024).
- Bruker has announced the acquisition of NanoString Technologies (veröffentlicht am 13, Mai 2024).
Andere vorgeschlagene Kontakte der Biotechnologie branche
Nachrichten
Neueste Pressemitteilungen nach AffaMed Therapeutics
- AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctiviti
- AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Patients after Cataract Surgery-Press Releases-AffaMed蔼睦医疗
- AffaMed Technologies Announces Licensing of EVOLUX®- a novel extended monofocal intraocular lens (IOL) designed to provide better intermediate vision and equivalent distance vision when compared to a standard monofocal IOL-Press Releases-AffaMed蔼睦医疗
- AffaMed Therapeutics Announces First Patient Treated in Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA ® for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery-Press Releases-AffaMed蔼睦医疗
- AffaMed Therapeutics Announces Clinical Trial Application Approval in Mainland China for Risuteganib (Luminate®) First-in-Class Candidate for the Treatment of Intermediate Dry AMD-Press Releases-AffaMed蔼睦医疗
- Press Releases-AffaMed蔼睦医疗
- AffaMed Therapeutics Announces Partner Vistagen Reports Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder-Press Releases-AffaMed蔼睦医疗
- AffaMed Therapeutics Announces Release of Headache Clinical Decision Support System-Press Releases-AffaMed蔼睦医疗
- AffaMed Therapeutics Announces Completion of Patient Enrollment in the Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA ® in Cataract Surgery Patients-Press Releases-AffaMed蔼睦医疗
- AffaMed Therapeutics Announces Partner Allgenesis Reports Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema -Press Releases-AffaMed蔼睦医疗
- View more press releases Close
Social media about AffaMed Therapeutics
- AffaMed Therapeutics auf Wikipedia, Google News & Yahoo Finance
- AffaMed Therapeutics auf LinkedIn, Twitter & YouTube
In Kontakt kommen
Jetzt seine Führungskräfte, darunter auch Vijay Karwal, per E-Mail kontaktieren. 
AffaMed Therapeutics unter +1 212... anrufen
